Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non-Small Cell Lung Cancer Treatment Setting.

Mason, Casey; Ellis, Peter G; Lokay, Kathy; Barry, Amanda; Dickson, Natalie; Page, Ray; Polite, Blase; Salgia, Ravi; Savin, Michael; Shamah, Corey; Socinski, Mark A

Mason, Casey; Ellis, Peter G; Lokay, Kathy; Barry, Amanda; Dickson, Natalie; Page, Ray; Polite, Blase; Salgia, Ravi; Savin, Michael; Shamah, Corey; Socinski, Mark A.

Afiliação

Mason C; Florida State University College of Medicine, Tallahassee, FL.
Ellis PG; UPMC Cancer Center, Pittsburgh, PA.
Lokay K; Via Oncology, Pittsburgh, PA.
Barry A; Via Oncology, Pittsburgh, PA.
Dickson N; Tennessee Oncology, Nashville, TN.
Page R; The Center for Cancer and Blood Disorders, Fort Worth, TX.
Polite B; University of Chicago Medicine, Chicago, IL.
Salgia R; City of Hope Comprehensive Cancer Center, Duarte, CA.
Savin M; Oregon Health & Science University, Portland, OR.
Shamah C; Aurora Health Care, Milwaukee, WI.
Socinski MA; Florida Hospital Cancer Institute, Orlando, FL.

J Clin Pathw ; 4(1): 49-54, 2018.

Article em En | MEDLINE | ID: mdl-31453358

Palavras-chave

biomarker testing; clinical pathways; non-small cell lung cancer; targeted therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Revista: J Clin Pathw Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google